Militia Capital Management LLC Buys New Position in Harrow, Inc. $HROW

Militia Capital Management LLC bought a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 23,519 shares of the company’s stock, valued at approximately $829,000. Militia Capital Management LLC owned 0.06% of Harrow as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. First Trust Advisors LP boosted its stake in shares of Harrow by 1.2% in the 1st quarter. First Trust Advisors LP now owns 154,096 shares of the company’s stock valued at $5,433,000 after purchasing an additional 1,865 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Harrow by 56.4% during the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after buying an additional 208,972 shares during the period. KBC Group NV bought a new position in Harrow during the first quarter worth $31,000. Blackhawk Capital Partners LLC raised its stake in Harrow by 27.9% during the first quarter. Blackhawk Capital Partners LLC now owns 172,332 shares of the company’s stock worth $6,076,000 after buying an additional 37,574 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Harrow in the first quarter valued at $1,829,000. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Down 2.2%

Harrow stock opened at $41.88 on Friday. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a 12-month low of $28.54 and a 12-month high of $54.85. The firm’s fifty day moving average is $38.97 and its 200 day moving average is $40.87. The company has a market capitalization of $1.56 billion, a PE ratio of -102.14 and a beta of 0.26.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The company had revenue of $44.20 million for the quarter, compared to the consensus estimate of $52.43 million. During the same period in the prior year, the company earned ($0.38) earnings per share. As a group, sell-side analysts predict that Harrow, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Harrow

In other news, CFO Andrew R. Boll purchased 3,500 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average cost of $29.90 per share, with a total value of $104,650.00. Following the purchase, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. This represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Adrienne L. Graves purchased 1,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were purchased at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director owned 1,000 shares in the company, valued at $31,070. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 12.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HROW shares. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research report on Friday, April 3rd. Cantor Fitzgerald lowered their price objective on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Monday. B. Riley Financial restated a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Finally, BTIG Research reaffirmed a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.43.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.